Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study

PURPOSE: Osimertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted for both EGFR sensitizing mutations and T790M resistance mutation in patients with non-small-cell lung cancer (NSCLC). We assessed efficacy and safety of osimertinib in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Yuxin, Xing, Puyuan, Hao, Xuezhi, Wang, Yan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826191/
https://www.ncbi.nlm.nih.gov/pubmed/31802944
http://dx.doi.org/10.2147/CMAR.S221434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826191/
https://www.ncbi.nlm.nih.gov/pubmed/31802944
http://dx.doi.org/10.2147/CMAR.S221434

Ejemplares similares